Our Technology
Introducing synVAX
VAXMED has invented a new vaccine platform technology called synVAX that will revolutionise the vaccine industry through new standardised procedures for vaccine design, construction and manufacturing. The speed of vaccine design and manufacturing is a key differentiation factor of our technology.
Are highly immunogenic: one vaccination is required to stimulate long lasting vaccine-induced immunity. No need for multiple vaccinations.
Our Vaccines
Provide broad protection against bacterial and viral infection through antibody and cell mediated immune responses
VAXMED vaccines are fully synthetic and the vaccine design follows a plug and play system. From vaccine concept design to proof of concept animal data in under 10 months, commencement of GMP manufacture in under 12 months. Even at small scale, large numbers of vaccines can be produced.
Have a high antigen payload: our vaccines can accommodate multiple antigens for better quality and broad immune responses and is a great platform for multivalent vaccines.
Manufacturing is being developed for readily available stirred tank bioreactors and utilises to a large extent single-use equipment keeping costs down.
Our production can be scaled. Laboratory-scale manufactured vaccines can be supplied for Australia and New Zealand. As a result of the unique VAXMED production system, vaccines can be manufactured within weeks in a standard clean room with the appropriate certification.
Why synVAX
synVAX vaccines have the potency of attenuated vaccines, the safety of inactivated vaccines, and the versatility of subunit vaccines. It combines all the advantages of the aforementioned vaccine classes but without their individual drawbacks. Vaccine design follows a plug and play system where manufacturing only requires one process for all synVAX-based vaccines.